Was Q2/H1 Good for Life Sciences?

View

Was Q2/H1 Good for Life Sciences?
Harry Wachob, PhD

August 6, 8:30AM
NOVA Suite 799, 505 West Olive Ave., Sunnyvale

Join us as we look at the life science industry and segment silos’ investments in Q2 and H1. Harry will be drawing from multiple sources, CB Insights/PwC, SVB, Fenwick & West, and Pullan Consulting and other recent information. After, we will also have time for open discussions.

Event Information

Event Topic:
Was Q2/H1 Good for Life Sciences?

Event Description:
Join us as we look at the life science industry and segment silos’ investments in Q2 and H1 . Harry will be drawing from multiple sources, PwC, SVB, Fenwick & West, and Pullan Consulting and other recent information. After, we will also have time for open discussions.

Date/Time:
Date(s) - 08/06/19
8:30 am - 10:30 am

Event Location:
NOVA - 505 West Olive Ave, Sunnyvale- Suite 799:

Speaker Information

Event Speaker:
Harry Wachob

Event Speaker Title:
President

Event Speaker Company:
Bio2Device Group

Event Speaker Bio:
Was Q2/H1 Good for Life Sciences?
Harry Wachob is the Founder and President of the Bio2Device Group. He is an experienced engineering leader in materials science, biomedical device engineering and R&D. He has directed and mentored multidisciplinary teams in solving complex technical issues in order to improve the safety, reliability, and performance of medical devices. Most recently, he was the Managing Materials Scientist at Xoft. Previously he was Director of Engineering for Aerogen, a biopharmaceutical company specializing in novel aerosol drug delivery. Prior to that, Harry was Managing Engineer at Exponent/Failure Analysis Associates where he guided research and development, and product failure investigations covering a broad range of medical and industrial applications. He received his engineering degrees in Materials Science & Engineering from Cornell University.

Event Details

Cost:
$0